A modified MethyLight assay predicts the clinical outcomes of anti‐epidermal growth factor receptor treatment in metastatic colorectal cancer-Reference-Cited by-同舟云学术

A modified MethyLight assay predicts the clinical outcomes of anti‐epidermal growth factor receptor treatment in metastatic colorectal cancer

Published:2022-01-28 Issue: Volume: Page:
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Ouchi Kota¹²^ORCID,Takahashi Shin¹²^ORCID,Okita Akira¹²,Sakamoto Yasuhiro³,Muto Osamu⁴,Amagai Kenji⁵,Okada Takaho⁶,Ohori Hisatsugu⁷,Shinozaki Eiji⁸,Ishioka Chikashi¹²⁹^ORCID

Affiliation:

1. Department of Clinical Oncology Institute of Development, Aging and Cancer (IDAC) Tohoku University Miyagi Japan

2. Department of Medical Oncology Tohoku University Hospital Miyagi Japan

3. Department of Medical Oncology Osaki Citizen Hospital Miyagi Japan

4. Department of Medical Oncology Akita Red Cross Hospital Akita Japan

5. Department of Gastroenterology Ibaraki Prefectural Central Hospital Ibaraki Cancer Center Ibaraki Japan

6. Department of Digestive Surgery Sendai Open Hospital Miyagi Japan

7. Department of Medical Oncology Ishinomaki Red Cross Hospital Miyagi Japan

8. Gastrointestinal Oncology Department The Cancer Institute Hospital of JFCR Tokyo Japan

9. Department of Clinical Oncology Tohoku University Graduate School of Medicine Miyagi Japan

Funder

Japan Agency for Medical Research and Development

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15252

Reference30 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray F;CA Cancer J Clin,2018

2. Cetuximab for the treatment of colorectal cancer;Jonker DJ;N Engl J Med,2007

3. Open‐label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy‐refractory metastatic colorectal cancer;Van Cutsem E;J Clin Oncol,2007

4. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets;Martini G;World J Gastroenterol,2017

5. S‐1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first‐line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open‐label, phase III, noninferiority trial;Yamada Y;Ann Oncol,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial;International Journal of Colorectal Disease;2024-06-11

2. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial;2024-02-22

3. Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers;Clinical Colorectal Cancer;2023-09

4. TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer;Clinical Colorectal Cancer;2023-09

5. Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201;Journal of Gastrointestinal Oncology;2023-04